Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy
Paul Szabolcs(Children's Hospital of Pittsburgh), Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Dima Yackoubov(Gamida Cell (Israel)), Ivan Lopez(Hospital de Sant Pau), Rabi Hanna(Cleveland Clinic), Joseph P. McGuirk(University of Kansas Medical Center), Caroline A. Lindemans(University Medical Center Utrecht), Guillermo Sanz(Instituto de Salud Carlos III), Amy K. Keating(Boston Children's Hospital), Nelson Hamerschlak(Hospital Israelita Albert Einstein), Stuart B. Levy(Federation University), Andrew R. Rezvani(Stanford Blood Center), Roei David Mazor(Assuta Medical Center), Nicole Karras(City Of Hope National Medical Center), Patrick J. Stiff(Loyola University Medical Center), John E. Wagner(Kings County Hospital Center), David Valcárcel(Vall d'Hebron Hospital Universitari)
Cited by 10
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Tackling antibiotic resistance
|Nature Reviews Microbiology|2011|1.1k